Boehringer Ingelheim starts STAT-C combination study...

According to Clinical Trails.gov, Boehringer Ingelheim has initiated a STAT-C combination study looking at their compounds BI 207127 (Non-nucleoside polymerase inhibitor) and BI 201335 (Protease inhibitor) plus Ribavirin. This study does not have an interferon component.

They are recruiting 302 naive patients who will be randomized to the following arms:
4 weeks of high dose TID BI 207127 + QD BI 201335 (protease inhibitor) + RBV
4 weeks of low dose TID BI 207127 and QD BI 201335 + RBV
24 or 48 weeks of high dose TID BI 207127 and QD BI 201335 + RBV
24 or 48 weeks of high dose BID BI 207127 and QD BI 201335 + RBV
24 or 48 weeks of high dose TID BI 207127 and QD BI 201335

The primary outcome measures are RVR and SVR. All sites are in the EU

http://clinicaltrials.gov/ct2/show/NCT01132313?term=hepatitis+OR+hep+OR+HCV&lup_s=05%2F01%2F2010&lup_d=30